Skip to main content

Table 2 Relative expression of the htid splice forms L, I, S and the HER-2 transcript in human breast cancer

From: In vivo evidence of htid suppressive activity on ErbB-2 in breast cancers over expressing the receptor

Sample

1

2

3

4

5

6

7

8

T/N/M/G status

2/1/1/3

1/0/0/3

4/1/x/2

3/1/1/3

2/1/1/3

2/1/1/3

1/2/0/2

2/1/0/3

Target gene

         

h tid- L

ΔCt

4,68

3,32

2,77

5,81

4,38

4.08

2,08

2,57

 

ΔΔCt

0,94

-0,43

-0,98

2,07

0,64

0,34

-1,66

-1,18

 

2 -ΔΔ Ct

0,52

1,35

1,97

0,24

0,64

0,79

3,16

2,27

Rel. expression (%)

52

135

197

24

64

79

316

227

h tid- I

ΔCt

1,55

2,99

2,21

2,89

0,77

0,82

1,88

0,35

 

ΔΔCt

0,54

1,28

1,20

1,88

-0,24

-0,19

0,87

-0,66

 

2 -ΔΔ Ct

0,69

0,41

0,44

0,27

1,18

1,14

0,55

1,58

Rel. expression (%)

69

41

44

27

118

114

55

158

h tid- S

ΔCt

14,55

15,61

15,34

15,84

13,39

13,43

14,75

14,22

 

ΔΔCt

-0,4

0,67

0,4

0,90

-1,55

-1,51

-0,19

-0,72

 

2 --ΔΔ Ct

1,32

0,63

0,76

0,54

2,93

2,85

1,14

1,65

Rel. expression (%)

132

63

76

54

293

285

114

165

HER- 2

ΔCt

1,63

0,44

0,29

-0,11

0,60

-0,69

-1,11

-2,37

 

ΔΔCt

3,95

2,76

2,61

2,21

1,72

1,63

1,21

-0,05

 

2 -ΔΔ Ct

0,06

0,15

0,16

0,22

0,30

0,32

0,43

1,04

Rel. expression (%)

6

15

16

22

30

32

43

104

Sample

9

10

11

12

13

14

15

 

T/N/M/G status

2/0/0/2

1/x/x/2

1/2/0/3

3/1/x/3

4/2/0/3

4/2/0/3

3/4/0/3

 

Target gene

         

h tid- L

ΔCt

3,47

3,43

4,08

0,68

3,44

3,89

2,08

 
 

ΔΔCt

-0,28

-0,31

0,34

-3,06

-0,31

0,15

-1,66

 
 

2 -ΔΔ Ct

1,21

1,24

0,79

8,34

1,24

0,90

3,16

 

Rel. expression (%)

121

124

79

834

124

90

316

 

h tid- I

ΔCt

2,40

0,06

1,77

0,37

-0,08

0,90

1,28

 
 

ΔΔCt

1,39

-1,06

0,76

-0,64

-1,09

0,11

0,27

 
 

2 -ΔΔ Ct

0,38

2,08

0,59

1,56

2,13

0,93

0,83

 

Rel. expression (%)

38

208

59

156

213

93

83

 

h tid- S

ΔCt

15,91

13,02

13,90

13,84

13,32

17,55

13,51

 
 

ΔΔCt

0,97

-1,92

-1,04

-1,10

-1,62

2,61

-1,43

 
 

2 -ΔΔ Ct

0,51

3,80

2,06

2,14

3,07

0,16

2,70

 

Rel. expression (%)

51

380

206

214

307

16

270

 

HER- 2

ΔCt

-2,63

-2,97

-3,00

-3,23

-3,40

-5,71

-6,31

 
 

ΔΔCt

-0,31

-0,65

-0,68

0,91

-1,08

-3,39

-3,99

 
 

2 -ΔΔ Ct

1,24

1,57

1,60

1,88

2,11

10,48

15.93

 

Rel. expression (%)

124

157

160

180

211

1048

1593

 
  1. The samples are sorted according to the increase of HER-2 expression. The average ΔCt values (n=3) are presented. The calculation of ΔΔCt involves substraction by the ΔCt calibrator value (normal sample), ΔΔCt = ΔCt (tumor sample) - ΔCt (normal sample). The SD of ΔΔCt is the same as the SD of the ΔCt. The ΔCt values of both the tumor and normal samples are standardized to HGPRT used as endogenous control. The values defined as increase of expression represent the relative (rel.) change/increase in expression of the defined target as compared to normal sample and are calculated as follows: 2-ΔΔCt × 100%. T, tumor extension: T1, to submucosa; T2, to muscle layer; T3, to subserosa; T4, to serosa. N, lymph node affection; M, metastasis; G, grading: G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; x, not defined.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us